GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT01677104

CompletedPhase NA

The Microvascular Function of GLP-1 and Its Analogues

The Microvascular Function of GLP-1 and Its Analogues in Humans, in Vivo: the Role of DPP-IV Inhibition

Lead sponsor

Katarina Kos

Assets

Exenatide / Liraglutide

Listed sites

Recruiting sites

—

Enrollment

estimated

Study population

Healthy volunteers, Obesity / overweight, Type 2 diabetes

Key I/E criterion

•BMI ≤25

Primary endpoint

•Skin blood flow

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01677104

Org study ID11/SW/0195

Secondary ID1204620Research and Development

Timeline

Milestones

Study first posted2012-08-31estimated

Last update posted2017-04-13actual

Study start2012-08 (month precision)

Primary completion2014-07actual (month precision)

Study completion2014-07actual (month precision)

Assets

Investigational agents

Exenatide Liraglutide

Study populations

Who this study enrolls

Healthy volunteersObesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Lean BMI ≤ 25.0 kg/m2

•Obese BMI ≥30.0kg/m2

•Non diabetic subjects and subjects with Type 2 diabetes on stable medication for at least 3 months

Exclusion criteria

•cardiovascular disease

•Raynaud's disease

•current treatment with any anti-hypertensive

•lipid lowering therapies

•severe hepatic impairment

•pregnancy and lactation

•subjects with Type 2 diabetes on insulin therapy

•subjects with Type 2 diabetes on sulphonylureas

•subjects with Type 2 diabetes on incretin based therapies

•subjects with Type 2 diabetes and peripheral vascular disease

•subjects with Type 2 diabetes and history of advanced retinopathy

•subjects with Type 2 diabetes and advanced nephropathy

•subjects with Type 2 diabetes with uncontrolled diabetes (HbA1c > 8.5%)

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Other clinical outcomes

1 endpoint

Primary/protocol endpoint/low confidence

skin blood flow

Time frame:3 hours

change from baseline, descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes.
Diabetologia2019 Sep (month)PMID31203378doi:10.1007/s00125-019-4918-xvia clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.